West Nile virus neutralization by US plasma-derived immunoglobulin products

Journal of Infectious Diseases

Volumn 196, Issue 3, 2007, Pages 435-440

  Planitzer, Christina B ^a   Modrof, Jens ^a   Kreil, Thomas R ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBSTITUTION THERAPY; UNITED STATES; VIRUS NEUTRALIZATION; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MICE, INBRED BALB C; UNITED STATES; VERO CELLS; WEST NILE FEVER; WEST NILE VIRUS;

EID: 34447649014     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/519392     Document Type: Article

References (30)

1. Smithburn KC, Hughes TP, Burke AW, Paul JH. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med Hyg 1940; Jun 11:471-92.
2. Petersen LR, Roehrig JT. West Nile virus: a reemerging global pathogen. Emerg Infect Dis 2001; 7:611-4.
3. Giladi M, Metzkor-Cotter E, Martin DA, et al. West Nile encephalitis in Israel, 1999: the New York connection. Emerg Infect Dis 2001; 7:659-61.
4. Busch MP, Wright DJ, Custer B, et al. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis 2006; 12:395-402.
5. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003; 290:511-5.
6. Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis 2003; 9:376-9.
7. Immune Deficiency Foundation. Diagnostic and clinical care guidelines for primary immunodeficiency diseases. Towson, MD: Immune Deficiency Foundation, 2006.
8. Centers for Disease Control and Prevention. Guidelines for surveillance, prevention, and control of West Nile virus infection - United States. MMWR Morb Mortal Wkly Rep 2000; 49:25-8.
9. Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001; 7:675-8.
10. Immune Deficiency Foundation. Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey. Towson, MD: Immune Deficiency Foundation, 2003.
11. Agrawal AG, Petersen LR. Human immunoglobulin as a treatment for West Nile virus infection. J Infect Dis 2003; 188:1-4.
12. Beasley DW, Li L, Suderman MT, Barrett AD. Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 2002; 296:17-23.
13. Beasley DW, Barrett AD. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 2002; 76:13097-100.
14. US Census Bureau. Annual estimates of the population for the United States, regions, states, and for Puerto Rico: April 1, 2000 to July 1, 2006 (NST-EST2006-01). Available at: http://www.census.gov/popest/states/NST-ann-est html. Accessed 23 January 2007.
15. Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 2003; 77:12941-9.
16. Kreil TR, Eibl MM. Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol 1997; 71:2921-7.
17. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 2003; 188:5-12.
18. Biggerstaff BJ, Petersen LR. Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion 2003; 43:1007-17.
19. Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases. West Nile virus: statistics, surveillance, and control. Available at: http://www.cdc.gov/ncidod/dvbid/westnile/ surv&controlCaseCount06_detailed.htm. Accessed 16 January 2007.
20. European Commission. Opinion of the scientific committee on medicinal products and medical devices on "The impact of arthropod borne diseases (including WNV) on the safety of blood used for transfusion as well as organs used for transplantation in the European community." In: Directorate C - public health and risk assessment. Brussels: European Commission, 2003:1-25.
21. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001; 358:261-4.
22. Hubálek Z, Halouzka J. West Nile fever - a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis 1999; 5:643-50.
23. Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI. West Nile encephalitis epidemic in southeastern Romania. Lancet 1998; 352:767-71.
24. Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases. Arboviral encephalitis cases in humans, 1964-2005 Available at: http://www.cdc.gov/ncidod/dvbid/arbor/arbocase.htm. Accessed 16 January 2007.
25. Committee of Infectious Diseases, American Academy of Pediatrics. Active and passive immunization. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red book: report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2006:1-98.
26. Centers for Disease Control and Prevention. West Nile Virus infections in organ transplant recipients - New York and Pennsylvania, August-September, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1021-3.
27. Marfin AA, Gubler DJ. West Nile encephalitis: an emerging disease in the United States. Clin Infect Dis 2001;33:1713-9.
28. Shimoni Z, Niven MJ, Pitlick S, Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001; 7:759.
29. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002; 137:173-9.
30. US National Institutes of Health. Clinical trials: Omr-IgG-am™ for treating patients with or at high risk for West Nile virus disease. Available at: http://www.clinicaltrials.gov/ct/show/NCT00069316. Accessed 24 January 2007.